Company Filing History:
Years Active: 2012-2015
Title: The Innovative Contributions of Dana D. Wood
Introduction
Dana D. Wood, based in Collegeville, PA, is a notable inventor with a remarkable record of four patents to his name. His work primarily focuses on the field of pharmacology, particularly through the development of antagonists for human proprotein convertase subtilisin-kexin type 9 (PCSK9), which plays a crucial role in cholesterol management and cardiovascular health.
Latest Patents
Wood's latest patents include two significant innovations related to PCSK9 antagonists. The first patent, designated 1B20, discloses antagonists that effectively inhibit PCSK9 function. This inhibition has substantial implications for the treatment of conditions associated with heightened PCSK9 activity. The invention encompasses not only the antagonists themselves but also the nucleic acids encoding these molecules, vectors, host cells, and various compositions. Similarly, his second patent, labeled 1D05, presents a parallel innovation in PCSK9 antagonists, providing detailed methodologies for the synthesis and application of these critical inhibitors.
Career Highlights
Throughout his distinguished career, Dana D. Wood has worked with prominent organizations, including Merck Sharp & Dohme Corporation and Merck Sharpe & Dohme Corp. His contributions in these environments have significantly advanced research and development in pharmacological treatments, paving the way for innovative therapeutic strategies.
Collaborations
Wood has collaborated with other accomplished professionals in the field, including colleagues Jon H. Condra and Rose M. Cubbon. Their collective expertise has fostered a collaborative atmosphere that promotes innovation and enhances the development of new medical therapies centered around PCSK9 inhibition.
Conclusion
Dana D. Wood's contributions to the field of pharmacology, particularly through his patent portfolio focused on PCSK9 antagonists, exemplify the impact of innovative thinking in modern medicine. His collaborations and career milestones reflect a dedication to advancing therapeutic options that improve patient outcomes in the realm of cholesterol management and cardiovascular health.